Clinical Guidance Library

PA Guidance Library

Twenty clinical guidance cards for headache care in primary care — covering PA mechanics, treatment evidence, coding, and the documentation language that determines whether a prior authorization is approved or denied.

Run a PA — free →

PA Mechanics

The rules of the PA system — what payers require, how to document it, and where submissions fail.

01
CGRP Preventive Therapies — What They Are, Who Qualifies, and How to Get Them ApprovedPA impact

CGRP-targeted preventives require documented failure of two oral preventive classes — here is what payers actually look for.

02
Medication Overuse Headache — When the Treatment Becomes the ProblemPA impact

MOH develops when acute medications are used too frequently — documenting it strengthens any CGRP PA submission.

03
Episodic vs. Chronic Migraine — Why the Distinction Drives EverythingPA impact

The episodic/chronic distinction determines which treatments qualify, which ICD-10 codes apply, and which denial pathways will be used against you.

04
Prior Preventive Failure Documentation — What Reviewers Actually Look ForPA impact

Step therapy denial is the most common preventable PA failure — reviewers need four data points per trial: agent, dose achieved, duration, and reason for stopping.

05
Migraine with Aura and Hormonal Contraception — A Safety and Documentation PriorityPA impact

Migraine with aura plus combined hormonal contraceptives multiplies stroke risk approximately four to eight times — WHO Category 4 requires switching to progestin-only or non-hormonal methods.

06
Behavioral and Lifestyle Treatment — What the Evidence Supports and When Payers Require ItPA impact

Biofeedback, CBT, and relaxation training have Level A evidence — document them as complementary therapy, not primary, to avoid weakening your PA.

07
The Acute Treatment Ladder — Getting the Step Therapy Right Before You SubmitPA impact

Gepant PAs require documented triptan failure or a specific contraindication — document each trial with agent, dose, timing, and outcome.

08
Pediatric and Adolescent Migraine — FDA Approvals, Off-Label Use, and PA ConsiderationsPA impact

Three CGRP mAbs have FDA pediatric approval — step therapy is reduced but not eliminated, and teratogenicity bypass is stronger for adolescents than adults.

09
Botox / OnabotulinumtoxinA — Chronic Migraine Only, and What the Documentation Actually RequiresPA impact

Botox requires G43.7xx, PREEMPT protocol documentation, and two oral preventive failures — submitting under an episodic code produces automatic denial.

Clinical Practice

Diagnosis, coding, referral, and emergency management with direct PA consequences.

10
Cluster Headache — Diagnosis, Bridge Treatment, and When to ReferPA impact

Cluster headache is not migraine — PA pathway, ICD-10 codes, oxygen as a DME benefit, and acute treatment are entirely different.

11
When to Refer to a Headache Specialist — and How to Manage the Gap

Most migraine patients don't need a specialist — but when they do, start preventive therapy now rather than waiting six months for the appointment.

12
Emergency Department Visits — Prevention, Documentation, and Closing the LoopPA impact

An ER visit is documented evidence of outpatient treatment failure — use it in PA language, build a rescue plan, and close the loop within one week.

13
New Daily Persistent Headache (NDPH) — A Rare Diagnosis That Is Easy to MisapplyPA impact

G44.52 produces automatic PA denial for CGRP mAbs and Botox — if the patient has a prior migraine history, correct the code to G43.7xx before submitting.

14
The Smart Phrase Library — EHR Templates for PA-Ready DocumentationPA impact

Copy-paste EHR templates generate PA-supporting documentation as a byproduct of routine clinical notes — available for every major headache documentation scenario.

Clinical Context

The science behind treatment decisions — and how to document it in the PA narrative.

15
Prodrome, Triggers, and the PA NarrativePA impact

Many reported 'triggers' are prodromal symptoms — reframe them as treatment windows, and document the distinction to strengthen the PA narrative.

16
Acute Medication Adequacy — Why Quantity Limits Undermine TreatmentPA impact

Standard 9-dose quantity limits force patients to ration acute medication — document the rationing behavior, the central sensitization consequences, and the ER visit history to support quantity override appeals.

17
Patient Beliefs That Affect Treatment Adherence and PA OutcomesPA impact

The 83% conversion gap starts in the exam room — navigate the five most common patient objections to migraine medication, and document each conversation to protect the PA narrative.

18
Four Hours — What Medical Education Didn't Cover About HeadachePA impact

Medical education allocates four hours to headache disorders. This card covers the minimum pathophysiology that changes how you document, prescribe, and file prior authorizations — science with direct operational consequences.

Instruments

Validated tools and devices: what they measure, how to administer them, and how scores appear in PA submissions.

19
Neuromodulation Devices — The OTC Options Your Patients May Already Be UsingPA impact

Four FDA-cleared neuromodulation devices are available for migraine — two without a prescription. Document patient device use before filing a PA: it satisfies non-pharmacological step therapy requirements and strengthens the clinical narrative.

20
MIDAS and HIT-6 — Administering Disability and Impact Instruments in Primary CarePA impactDraft

MIDAS counts lost days; HIT-6 measures impact. Both take under two minutes chairside and function as objective anchors in PA submissions, referral letters, and specialist communication — more defensible than narrative self-assessment.